[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 124, "auditRisk": 8, "boardRisk": 5, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 4, "previousClose": 5.25, "open": 5.0, "dayLow": 4.66, "dayHigh": 5.46, "regularMarketPreviousClose": 5.25, "regularMarketOpen": 5.0, "regularMarketDayLow": 4.66, "regularMarketDayHigh": 5.46, "beta": 1.828, "forwardPE": -1.3121548, "volume": 4385276, "regularMarketVolume": 4385276, "averageVolume": 1176983, "averageVolume10days": 4002750, "averageDailyVolume10Day": 4002750, "bid": 4.71, "ask": 4.76, "bidSize": 300, "askSize": 600, "marketCap": 337312704, "fiftyTwoWeekLow": 3.93, "fiftyTwoWeekHigh": 29.42, "priceToSalesTrailing12Months": 8.316388, "fiftyDayAverage": 11.2132, "twoHundredDayAverage": 14.2451, "currency": "USD", "enterpriseValue": -106316144, "floatShares": 51591114, "sharesOutstanding": 71013200, "sharesShort": 18533393, "sharesShortPriorMonth": 16637859, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.261, "heldPercentInsiders": 0.038039997, "heldPercentInstitutions": 1.20734, "shortRatio": 27.85, "shortPercentOfFloat": 0.5273, "bookValue": 6.46, "priceToBook": 0.7352941, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -218904000, "trailingEps": -3.26, "forwardEps": -3.62, "enterpriseToRevenue": -2.621, "enterpriseToEbitda": 0.512, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "ZNTL", "underlyingSymbol": "ZNTL", "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1585920600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "39a4bee6-8ddb-3930-b936-d5bcf9eb8cf7", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.75, "targetHighPrice": 25.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.7, "targetMedianPrice": 8.5, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 488984000, "totalCashPerShare": 6.886, "ebitda": -207447008, "totalDebt": 45355000, "quickRatio": 8.923, "currentRatio": 9.194, "totalRevenue": 40560000, "debtToEquity": 9.886, "revenuePerShare": 0.594, "returnOnAssets": -0.24933, "returnOnEquity": -0.5187, "freeCashflow": -75015000, "operatingCashflow": -210512992, "grossMargins": 1.0, "operatingMargins": -0.61057997, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]